Families Report Positive Experiences with Genetic Testing for Adult-Onset Conditions
Study of 25 families finds no evidence of hypothetical harms from disclosing adult-onset genetic results to adolescents.
Summary
Researchers studied families who received genetic testing results for conditions that don't manifest until adulthood, addressing long-standing concerns about potential psychological harm to children. The study followed 25 participants from families with known genetic variants, interviewing parents and adolescents at 1 and 12 months after disclosure. Contrary to theoretical concerns about distress, discrimination, or family dysfunction, families generally reported positive or neutral experiences. Most felt the information was beneficial despite not being immediately medically actionable. The findings challenge current guidelines that recommend deferring such testing until adulthood.
Detailed Summary
A groundbreaking study challenges decades of medical orthodoxy about genetic testing in children by providing the first empirical evidence that families handle adult-onset genetic results better than experts predicted. The Pediatric Reporting of Genomic Results Study (PRoGRESS) followed families through Geisinger's MyCode program, which screens for pathogenic variants in genes consistent with professional guidelines.
Researchers conducted in-depth interviews with 25 participants from families with known genetic variants - 8 with adult-onset conditions (like BRCA1/2 for breast cancer, Lynch syndrome genes) and 17 with pediatric-onset conditions. All adolescent participants (ages 11-17) were aware of their genetic test results. The study used rigorous qualitative methodology including rapid assessment and interpretative phenomenological analysis.
The results directly contradict theoretical concerns that have shaped medical guidelines for decades. Families reported predominantly positive or neutral experiences with learning genetic results, with no evidence of the hypothetical harms cited in professional recommendations - including increased distress, worsened self-image, negative family functioning, or loss of future autonomy. Parents and adolescents consistently felt the information was beneficial despite not being immediately medically actionable.
The study's longitudinal design revealed that positive attitudes persisted over time, with marked similarity between 1-month and 12-month interviews. This suggests that initial positive reactions weren't just temporary coping mechanisms but reflected genuine adaptation to the genetic information.
These findings have immediate clinical implications for genetic counselors, pediatricians, and families facing genetic testing decisions. The research provides evidence-based guidance for supporting families through genetic disclosure and suggests that current restrictive guidelines may be unnecessarily limiting family autonomy. However, the study was limited to families who already had known variants and chose to participate, potentially representing a more motivated population.
Key Findings
- 25 families with genetic variants reported predominantly positive or neutral experiences with genetic disclosure
- No evidence found of hypothetical harms including distress, discrimination, or family dysfunction
- Families consistently felt genetic information was beneficial despite not being immediately medically actionable
- Positive attitudes persisted from 1-month to 12-month follow-up interviews
- Study included 8 families with adult-onset conditions and 17 with pediatric-onset conditions
- All adolescent participants (ages 11-17) were successfully informed of their genetic test results
- Response rate of 49% (25 out of 51 eligible participants) for qualitative interviews
Methodology
Qualitative study using semi-structured interviews with parents and adolescents from families with known pathogenic/likely pathogenic variants identified through Geisinger's MyCode program. Interviews conducted at 1 and 12 months post-disclosure using interpretative phenomenological analysis. Sample included 25 participants representing 14 different genes across adult-onset and pediatric-onset conditions.
Study Limitations
Study limited to families who already had known genetic variants and chose to participate, potentially representing a more motivated population. Sample size was relatively small at 25 participants. Families were recruited from a single health system's genomic screening program, which may limit generalizability to other populations or healthcare settings.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.